| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20060528 | HPV | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS20060497 | HPV | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS44014712 | HTLV-1 | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS44016571 | HTLV-1 | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS44016572 | HTLV-1 | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS44037020 | HTLV-1 | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS44050497 | HTLV-1 | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS44050498 | HTLV-1 | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS44050499 | HTLV-1 | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
| TVIS44050500 | HTLV-1 | ENSG00000152818.20 | protein_coding | UTRN | No | No | 7402 | P46939 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | UTRN |
|---|---|
| DrugBank ID | DB01593 |
| Drug Name | Zinc |
| Target ID | BE0005835 |
| UniProt ID | P46939 |
| Regulation Type | |
| PubMed IDs | 17009962 |
| Citations | Hnia K, Zouiten D, Cantel S, Chazalette D, Hugon G, Fehrentz JA, Masmoudi A, Diment A, Bramham J, Mornet D, Winder SJ: ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site. Biochem J. 2007 Feb 1;401(3):667-77. |
| Groups | Approved; Investigational |
| Direct Classification | Homogeneous transition metal compounds |
| SMILES | [Zn] |
| Pathways | Dihydropyrimidinase Deficiency; Rofecoxib Action Pathway; Losartan Action Pathway; AICA-Ribosiduria; Canavan Disease; Quinapril Action Pathway; Alkaptonuria; Eprosartan Action Pathway; gamma-Glutamyltransferase Deficiency; Pterine Biosynthesis; Sulindac Action Pathway; Rescinnamine Action Pathway; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); beta-Ureidopropionase Deficiency; Vitamin B6 Metabolism; Retinol Metabolism; Valsartan Action Pathway; Valdecoxib Action Pathway; Irbesartan Action Pathway; Adenosine Deaminase Deficiency; Hawkinsinuria; Methionine Metabolism; Ramipril Action Pathway; Benazepril Action Pathway; beta-Alanine Metabolism; Aspartate Metabolism; Diclofenac Action Pathway; Galactosemia |
| PharmGKB | PA451956 |
| ChEMBL | CHEMBL1201279 |
